0001493152-26-014654
SEC filingInterpace Biosciences reported Q4 and FY 2025 revenue of $9.2M and $38.7M with income from continuing operations of $22.8M and $25.0M driven by a one-time non-cash tax adjustment, alongside strong thyroid revenue growth.
Interpace Biosciences announced Q4 and full year 2025 results highlighting a strategic shift to a thyroid-only diagnostics company following PancraGEN discontinuation in May 2025. GAAP revenue declined due to the discontinued operations but showed robust pro forma growth of 20% in Q4 and 17% for the year, reflecting core thyroid business strength. Thyroid-specific metrics were standout, with Q4 revenue up 14% YoY and full year up 21%, driven by 11% and 13% volume increases respectively, plus 5% higher average revenue per test. Gross margins improved to 66% in Q4 from 64% YoY GAAP and 57% pro forma, signaling operational efficiency gains from AI, automation, and lab investments. Operating income remained positive at $1.6M in Q4 despite topline pressure. The headline $22.8M Q4 and $25.0M FY income from continuing operations stemmed primarily from a one-time, non-cash release of deferred tax valuation allowance, masking underlying profitability where pro forma results showed losses. Balance sheet strengthened markedly with debt fully repaid in Q4, cash up to $2.5M from $1.5M YoY, and equity turning positive at $22.4M from a $2.2M deficit. Business highlights included 19% lower DSO, 20% faster turnaround, 6% higher volume per account, and 9% account growth. Management expressed confidence in 2026 thyroid revenue growth of approximately 16% YoY, supported by commercial momentum and productivity initiatives. CEO Tom Burnell emphasized the resilience of ThyGeNEXT and ThyraMIR v2 platforms in aiding physician decisions.